Tag Archives: Dolutegravir

ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF

Metabolic syndrome – including obesity – developed significantly more frequently in people who received dolutegravir, tenofovir alafenamide (TAF) and emtricitabine compared to other regimens in the South African ADVANCE study, Michelle Moorhouse reported on Thursday at the 17th European AIDS Conference in Basel, Switzerland. Furthermore, updated follow-up from the study showed that close to 60%… Read More »

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half of people with very high viral loads taking either regimen had a detectable viral load after 48 weeks, the HIV Glasgow 2018 conference heard. Despite the non-inferiority of efavirenz-based… Read More »